Cargando…
Recent advances on blinatumomab for acute lymphoblastic leukemia
Although complete remission rate of B cell acute lymphoblastic leukemia (B-ALL) has improved significantly over the past few decades, patients with relapsed/refractory ALL still have dismal outcome. Tyrosine kinase inhibitors, antibody–drug conjugates and chimeric antigen receptor T cell therapy are...
Autores principales: | Zhao, Juanjuan, Song, Yongping, Liu, Delong |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6833142/ https://www.ncbi.nlm.nih.gov/pubmed/31709129 http://dx.doi.org/10.1186/s40164-019-0152-y |
Ejemplares similares
-
Advancements in Therapy for Acute Lymphoblastic Leukemia: Blinatumomab
por: Hladnik,1, Lindsay, et al.
Publicado: (2016) -
Biomarkers associated with blinatumomab outcomes in acute lymphoblastic leukemia
por: Wei, Andrew H., et al.
Publicado: (2021) -
Potential for bispecific T-cell engagers: role of blinatumomab in acute lymphoblastic leukemia
por: Le Jeune, Caroline, et al.
Publicado: (2016) -
Clinical use of blinatumomab for B-cell acute lymphoblastic leukemia in adults
por: Lee, Kum Ja, et al.
Publicado: (2016) -
Clinical trial update on bispecific antibodies, antibody-drug conjugates, and antibody-containing regimens for acute lymphoblastic leukemia
por: Liu, Delong, et al.
Publicado: (2019)